Companies Dominating the Bivalirudin and Desmopressin Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Hainan Shuangcheng Pharmaceuticals Co. Ltd.
- AmbioPharm Inc.
- Abott India Limited (India)
- The Medicines Company
- Sun Pharmaceuticals Industries Limited
- Ferring Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Chengdu Shengnuo Biopharm Co. Ltd.
- ScinoPharm Taiwan Ltd
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Bivalirudin and Desmopressin Market size is projected to growing at around 5.1% CAGR during the forecast period i.e., between 2025-2037.
Rising prevalence of cardiovascular diseases along with increasing number of elderly people suffering from nocturia will impel the market growth.
North America industry is expected to hold largest revenue share by 2037, as coronary artery disease (CAD) prevalence among the population resulted in increasing percutaneous coronary intervention (PCI) procedures in the region.
The major players in the market are Pfizer, Inc., Hainan Shuangcheng Pharmaceuticals Co. Ltd., AmbioPharm Inc., Abott India Limited, The Medicines Company, Sun Pharmaceuticals Industries Limited, Ferring Pharmaceuticals, and others.
